Abstract
There are very limited data on the efficacy of medical therapies for upper gastrointestinal Crohn's disease (CD), and no data exist for the efficacy of IL-23 p19 inhibition on upper gastrointestinal CD. We present the case of a 21-year-old man with severe gastric and duodenal CD, who demonstrated complete clinical and endoscopic response to risankizumab after 28 weeks of therapy.